News

The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Wegovy News Pushes Novo Nordisk Stock Higher

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...
24/7 Wall St.12h

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk A/S: Novo Nordisk to present Wegovy and Ozempic data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...